GT Biopharma's three largest insider shareholders as of September 29, 2026 are Michael Martin Breen (Executive Chairman/Interim Ceo, 6 shares), Manu Ohri (Cfo Secretary, 2 shares), Manu Ohri (Cfo Secretary, 0 shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Michael Martin Breen | Executive Chairman/Interim Ceo | 6 | 0 | 6 | 74.0% | 15 Aug, 2023 |
| 2 | Manu Ohri | Cfo Secretary | 0 | 2 | 2 | 26.0% | 15 Aug, 2023 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 04 Sep, 2025 | Hilary Kramer | Director | Acquired A | 31,250 | $0.00 | $0 | 0 | Direct |
| 04 Sep, 2025 | Alan Louis Urban | Chief Financial Officer | Acquired A | 50,000 | $0.00 | $0 | 0 | Direct |
| 04 Sep, 2025 | Michael Martin Breen | Ceo And Director | Acquired A | 100,000 | $0.00 | $0 | 0 | Direct |
| 04 Sep, 2025 | Charles J Casamento | Director | Acquired A | 62,500 | $0.00 | $0 | 0 | Direct |
| 04 Sep, 2025 | David C. Mun-Gavin | Director | Acquired A | 31,250 | $0.00 | $0 | 0 | Direct |
| 04 Sep, 2025 | Michael Martin Breen | Ceo And Director | Acquired A | 100,000 | $0.00 | $0 | 0 | Direct |
| 04 Sep, 2025 | Alan Louis Urban | Chief Financial Officer | Acquired A | 50,000 | $0.00 | $0 | 0 | Direct |
| 04 Sep, 2025 | Michael Martin Breen | Ceo And Director | Acquired A | 100,000 | $0.00 | $0 | 0 | Direct |
| 17 Oct, 2024 | Alan Louis Urban | Chief Financial Officer | Acquired A | 23,335 | $0.00 | $0 | 0 | Direct |
| 11 Aug, 2023 | Manu Ohri | Cfo Secretary | Acquired A | 200,000 | $43,961.99 | $8.79Bn | 1 | Direct |
| 11 Aug, 2023 | Michael Martin Breen | Executive Chairman/Interim Ceo | Acquired A | 200,000 | $43,961.99 | $8.79Bn | 6 | Direct |
| 11 Aug, 2023 | Manu Ohri | Cfo Secretary | Disposed J | 200,000 | $43,961.99 | $8.79Bn | 0 | Direct |
| 11 Aug, 2023 | Manu Ohri | Cfo Secretary | Acquired J | 200,000 | $43,961.99 | $8.79Bn | 2 | Indirect |
| 16 Jun, 2023 | Charles J Casamento | Director | Acquired A | 500,000 | $0.00 | $0 | 3 | Direct |
| 11 Apr, 2023 | Michael Martin Breen | Executive Chairman/Interim Ceo | Acquired P | 50,000 | $76,588.83 | $3.83Bn | 4 | Direct |
| 06 Apr, 2023 | Manu Ohri | Cfo Secretary | Acquired P | 50,000 | $76,588.83 | $3.83Bn | 0 | Indirect |
| 27 Jan, 2023 | Michael Martin Breen | Exec Chairman And Interim Ceo | Acquired A | 500,000 | $0.00 | $0 | 3 | Direct |
| 27 Jan, 2023 | Manu Ohri | Chief Financial Officer | Acquired A | 500,000 | $0.00 | $0 | 3 | Direct |
| 27 Jan, 2023 | Rajesh C Md Shrotriya | Director | Acquired A | 500,000 | $0.00 | $0 | 3 | Direct |
| 27 Jan, 2023 | Bruce Wendel | Director | Acquired A | 500,000 | $0.00 | $0 | 3 | Direct |